Drugs / BI 671800
last change Dec 2013 re-read 2 minutes ago

BI 671800

also known as Actimis

Small molecule targets PTGDR2 via inhibition

Developed for
asthma · seasonal allergic rhinitis
Investigated by
Boehringer Ingelheim

Trials 8 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT01216384 Oct → Dec 2010 asthma, perennial allergic rhinitis Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT01215773 Oct → Dec 2010 Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT01205373 Sep → Oct 2010 Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02221388 Feb → Jul 2010 Boehringer Ingelheim Completed No outcome recorded
Phase 24 trials
Phase 2 NCT01103349 Apr 2010 → Aug 2011 asthma Boehringer Ingelheim Completed No outcome recorded
Phase 2 NCT01092143 Mar 2010 → Mar 2011 asthma Boehringer Ingelheim Completed No outcome recorded
Phase 2 NCT01090024 Mar 2010 → Feb 2011 asthma Boehringer Ingelheim Completed No outcome recorded
Phase 2 NCT01007721 Oct 2009 → Apr 2010 asthma, seasonal allergic rhinitis Boehringer Ingelheim Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as BI 671800 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01103349
7

NCT02221388

NCT01215773

NCT01205373

NCT01216384

NCT01007721

NCT01090024

NCT01092143

Known as Actimis ChEMBL registry synonym — accepted as the source's own label CHEMBL551813
Action Inhibit “G protein-coupled receptor 44 antagonist” CHEMBL551813
1

“oral CRTH2 antagonist BI 671800” PMID 24332218 Dec 2013

Modality Small molecule CHEMBL551813
Route Oral oral CRTH2 antagonist BI 671800” PMID 24332218 Dec 2013
Target PTGDR2 “G protein-coupled receptor 44 antagonist” CHEMBL551813